South Africa has one of the highest burdens of TB and (Drug Resistant) DR-TB in the world, with around 20,000 people diagnosed with DR-TB in 2015. In Khayelitsha, Western Cape, which has some of the country’s highest rates of DR-TB, MSF runs a strengthened regimen programme that incorporates new drugs into treatment regimens for DR-TB patients including Delamanid and Bedaquiline. At the International Lung Health Conference in Liverpool this October, MSF will share experiences and preliminary data on patient outcomes of using delamanid, including from South Africa.
Tb Briefingpaper Final
pdf — 1.29 MB